SenzaGen Valuation
| SENZA Stock | SEK 6.95 0.10 1.42% |
At this time, the company appears to be overvalued. SenzaGen AB has a current Real Value of kr6.42 per share. The regular price of the company is kr6.95. Our model measures the value of SenzaGen AB from inspecting the company fundamentals such as Return On Equity of -0.32, operating margin of (0.95) %, and Shares Outstanding of 24.19 M as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that SenzaGen's price fluctuation is somewhat reliable at this time. Calculation of the real value of SenzaGen AB is based on 3 months time horizon. Increasing SenzaGen's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the SenzaGen stock is determined by what a typical buyer is willing to pay for full or partial control of SenzaGen AB. Since SenzaGen is currently traded on the exchange, buyers and sellers on that exchange determine the market value of SenzaGen Stock. However, SenzaGen's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6.95 | Real 6.42 | Hype 6.95 | Naive 6.89 |
The intrinsic value of SenzaGen's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence SenzaGen's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of SenzaGen AB helps investors to forecast how SenzaGen stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of SenzaGen more accurately as focusing exclusively on SenzaGen's fundamentals will not take into account other important factors: SenzaGen Total Value Analysis
SenzaGen AB is at this time projected to have takeover price of 255.67 M with market capitalization of 308.55 M, debt of 714 K, and cash on hands of 69.16 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the SenzaGen fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
255.67 M | 308.55 M | 714 K | 69.16 M |
SenzaGen Investor Information
About 37.0% of the company outstanding shares are owned by corporate insiders. The book value of SenzaGen was at this time reported as 4.08. The company recorded a loss per share of 1.35. SenzaGen AB had not issued any dividends in recent years. Based on the analysis of SenzaGen's profitability, liquidity, and operating efficiency, SenzaGen AB is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.SenzaGen Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. SenzaGen has an asset utilization ratio of 11.53 percent. This implies that the Company is making kr0.12 for each dollar of assets. An increasing asset utilization means that SenzaGen AB is more efficient with each dollar of assets it utilizes for everyday operations.SenzaGen Ownership Allocation
SenzaGen AB shows a total of 24.19 Million outstanding shares. SenzaGen AB maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.SenzaGen Profitability Analysis
The company reported the revenue of 15.42 M. Net Loss for the year was (31.35 M) with profit before overhead, payroll, taxes, and interest of 9.45 M.About SenzaGen Valuation
The stock valuation mechanism determines SenzaGen's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of SenzaGen AB based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of SenzaGen. We calculate exposure to SenzaGen's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of SenzaGen's related companies.SenzaGen AB, together with its subsidiary, markets, sells, and performs in vitro genomic allergen rapid detection sensitization tests for the screening of pharmaceutical candidates, and safety assessment of chemicals and cosmetic ingredients in Sweden and internationally. SenzaGen AB was incorporated in 2010 and is headquartered in Lund, Sweden. SenzaGen is traded on Stockholm Stock Exchange in Sweden.
8 Steps to conduct SenzaGen's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates SenzaGen's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct SenzaGen's valuation analysis, follow these 8 steps:- Gather financial information: Obtain SenzaGen's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine SenzaGen's revenue streams: Identify SenzaGen's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research SenzaGen's industry and market trends, including the size of the market, growth rate, and competition.
- Establish SenzaGen's growth potential: Evaluate SenzaGen's management, business model, and growth potential.
- Determine SenzaGen's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate SenzaGen's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for SenzaGen Stock Analysis
When running SenzaGen's price analysis, check to measure SenzaGen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SenzaGen is operating at the current time. Most of SenzaGen's value examination focuses on studying past and present price action to predict the probability of SenzaGen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SenzaGen's price. Additionally, you may evaluate how the addition of SenzaGen to your portfolios can decrease your overall portfolio volatility.